1-1000 Kilograms
$700.00
≥1001 Kilograms
$450.00
Product Description
Lapatinib produced by glaxosmithkline. Epidermal growth factor receptor tyrosine kinase inhibitor, an oral administration of small molecules. Mainly used for joint card of capecitabine in the treatment of erbB-2 overexpression, who previously received including anthracyclines and paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. When taking the need to pay attention to its adverse reactions.
In the experiment of Chinese hamster, no carcinogenic effect was found, and no genetic toxicity was found. There was no effect on mating ability and fertility of rats under high dose. There are 1 cases reported in pregnant women in March before taking lapatinib, full-term pregnancy after the birth of healthy children .
Lapatinib in Indonesia and capecitabine combination in the treatment of breast cancer, the effect is better, and of anthracene ring antibiotics, taxanes and trastuzumab resistant patients effective, mild side effects, for advanced or metastatic breast cancer patients and a drug treatment.
Certification of Analysis
Name: Lapatinib Ditosylate | ||
CAS No.: | 388082-78-8 | |
Content: | >99% | |
Appearance: | A white,Crystalline Powder | |
Formula: | C29H26ClFN4O4S | |
Molecular Weight | 581.06 | |
Moisture: | <1mg/mL | |
Loss on Drying: | ≤0.2% | |
Residue on ignition: | ≤0.1% | |
Boiling Point: | 750.7°C at 760 mmHg | |
Flash(ing) point: | 407.8°C | |
Stability: | at -20°C 2 years | |
Heavy Metals: | ≤10PPM | |
Acidity or Alkalinity: | Conform | |
Chloride: | Conform | |
Readily Carbonizable Substances: | Conform | |
Ordinary Impurities: | Conform |
Function&Application
Lapatinib is a targeted therapy of breast cancer drug, is a tyrosine kinase inhibitor, can effectively inhibit the human epidermal growth factor receptor -1 (ErbB1) and human epidermal growth factor receptor (ErbB2) tyrosine kinase activity of -2. It is unique in that it can play a role in a variety of ways, so that breast cancer cells can not receive the signal needed for growth. The mechanism of action is to inhibit the intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites to prevent phosphorylation and activation of tumor cells, and to block the down-regulation of signaling by EGFR (ErbB-1) and HER2 (ErbB-1) homogeneous and heterogeneous two aggregates.
Molecular targeted therapy for breast cancer is the treatment of oncogenes and related expression products related to the occurrence and development of breast cancer. Molecular targeted drugs control cell gene expression by blocking the signal transduction of tumor cells or related cells, thereby inhibiting or killing tumor cells.
Qingdao Sigma chemical Co., Ltd is is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates, food and feed additives, herbal extracts, agrochemicals and fine chemicals etc.
The aim of Qingdao Sigma chemical Co., Ltd is a quality policy that "Elements in the system all have been satisfied, Personnel has been trained; Every batch of material is checked, Each procedure guarantees the quality; Every bag of our products is top grade, Service is thoughtful all the time, quality and reputation to increase market share and promote enterprise development. The quality, colors and forms of our products have reached a high level in related chemical industry, which relies on characteristic and advanced processing technology and it has gained a high and reliable reputation from customers at both quality and services.
Scan the QR code with your phone, or visit the URL